Symphony Evolution, Inc.
Records under this name other than patents Symphony Evolution, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Symphony Evolution, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,576,074 | Receptor-Type Kinase Modulators and Methods of Use Term ended Term ended May 4, 2026 · High confidence | Term ended | Term ended May 4, 2026 | High confidence |
| US 9,956,221 | Use of a receptor-type kinase modulator for treating polycystic kidney disease Lapsed on the fee record Ended May 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2026 | From the USPTO record |
| US 8,658,654 | Receptor-Type Kinase Modulators and Methods of Use Term ended Term ended Mar 28, 2025 · High confidence | Term ended | Term ended Mar 28, 2025 | High confidence |
| US 9,364,479 | Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease Lapsed on the fee record Ended Jun 14, 2024 · High confidence | Lapsed on the fee record | Ended Jun 14, 2024 | High confidence |
| US 7,989,661 | Human ADAM-10 inhibitors Lapsed on the fee record Ended Aug 2, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 2, 2023 | From the USPTO record |
| US 9,796,704 | Substituted quinazolines as receptor-type kinase inhibitors Term ended Term ended Jul 30, 2023 · From the USPTO record | Term ended | Term ended Jul 30, 2023 | From the USPTO record |
| US 9,359,332 | Processes for the Preparation of Substituted Quinazolines Term ended Term ended Jul 14, 2023 · High confidence | Term ended | Term ended Jul 14, 2023 | High confidence |
| US 10,266,518 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof Term ended Ended no later than Jul 14, 2023 · From the USPTO record | Term ended | Ended no later than Jul 14, 2023 | From the USPTO record |
| US 7,629,341 | Human ADAM-10 inhibitors Lapsed on the fee record Ended Dec 8, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 8, 2021 | From the USPTO record |
| US 8,426,415 | Human ADAM-10 inhibitors Lapsed on the fee record Ended Apr 23, 2021 · From the USPTO record | Lapsed on the fee record | Ended Apr 23, 2021 | From the USPTO record |